GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Therapeutic Solutions International TSOI · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 2 Nov 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$98,994

FY2014FY2023

Net income

−$2.2m

FY2014FY2023

Free cash flow

−$1.1m

FY2014FY2023

Shareholders' equity

$1.1m

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$98,994$206,767$145,956$62,681$27,495$3,484$2,851$1,911$268,892—
Research and development$560,654$1.4m$794,750$561,990$27,685$74,970$25,106$10,990$10,990$10,990
Operating income−$2.0m−$3.3m−$2.3m−$1.8m−$1.0m−$1.2m−$884,267−$570,935−$327,105−$327,105
Net income−$2.2m−$3.8m−$3.0m−$2.2m−$1.7m−$1.9m−$995,472−$586,441−$288,750−$288,750
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$3.3m$3.6m$1.7m$603,474$311,000$206,931$26,525$104,875$201,217$201,217
Cash and short-term investments$27,823$18,040$94,036$252,147$26,410$22,397$29$21,910$2,894—
Total liabilities$2.0m$2.2m$2.5m$2.4m$2.3m$2.0m$1.3m$759,707$332,505$332,505
Debt$888,064$1.1m$1.1m$1.0m$981,622$504,271$456,660$296,951$30,000$27,174
Shareholders' equity$1.1m$1.2m−$804,982−$1.8m−$2.0m−$1.8m−$1.3m−$654,832−$131,288−$131,288
Shares outstanding3,803m2,610m2,267m2,234m1,615m2,695m983m570m570m301m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$1.1m−$1.0m−$718,922−$663,079−$310,714−$469,172−$366,717−$385,741−$59,619−$332,536
Capital spending−$16,158−$200,000−$260,565−$5,448−$5,448−$5,448−$5,448———
Free cash flow−$1.1m−$1.2m−$979,487−$668,527−$316,162−$474,620−$372,165−$385,741−$59,619−$332,536

Latest quarters

By quarter end

Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022
Revenue$19,667$20,005$21,814$23,833$25,730$26,308$23,123$8,579
Operating income−$2.0m−$404,038−$673,241−$556,771−$457,335−$542,506−$429,867−$758,628
Net income−$1.0m−$390,046−$585,141−$427,492−$602,041−$562,400−$270.4m−$1.3m
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.07-0.00
Capital spending——−$16.0m—————
Total assets$3.6m$3.8m$4.1m$3.3m$3.5m$3.5m$3.5m$3.6m
Cash and short-term investments$9,233$8,318$53,477—$90,138$123,083$18,531$18,040
Debt$850,895$875,574$833,683$5,512$784,239$780,830$1.1m$1.1m
Shareholders' equity$1.3m$1.3m$1.4m$1.1m$1.3m$1.5m$1.2m$1.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue16.5%95.3%—
Operating income2.4%10.6%8.9%
Net income-0.5%3.1%14.7%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1722.2%-1831.2%-2138.5%—
Net margin-1957.0%-2166.6%-2697.1%—

Valuation history

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.0-0.1-0.3-0.1-0.0-0.0-0.0—
Price to sales0.50.95.52.80.511.42.60.3

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return1948%-60%-85%-69%239%755%0%17%655%280%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.